The initial event by which M-tropic HIV strains gain access to cells is via interaction of the viral envelope protein gp120 with the host cell CCR5 coreceptor and CD4. Inhibition of this event reduces viral fusion and entry into cells in vitro. The authors have employed BacMam baculovirus-mediated gene transduction to develop a cell/cell fusion assay that mimics the HIV viral/cell fusion process and allows high-throughput quantification of this fusion event. The assay design uses human osteosarcoma (HOS) cells stably transfected with cDNAs expressing CCR5, CD4, and long terminal repeat (LTR)-luciferase as the recipient host cell. An HEK-293 cell line transduced with BacMam viral constructs to express the viral proteins gp120, gp41, tat, and rev represents the virus. Interaction of gp120 with CCR5/CD4 results in the fusion of the 2 cells and transfer of tat to the HOS cell cytosol; tat, in turn, binds to the LTR region on the luciferase reporter and activates transcription, resulting in an increase in cellular luciferase activity. In conclusion, the cell/cell fusion assay developed has been demonstrated to be a robust and reproducible high-throughput surrogate assay that can be used to assess the effects of compounds on gp120/CCR5/ CD4-mediated viral fusion into host cells.
INTRODUCTION
H IV gains entry into host cells by means of the CD4 receptor and at least one coreceptor expressed on the surface of the cell membrane. 1, 2 M-tropic strains of HIV use the chemokine receptor CCR5, 3 whereas T-tropic strains of HIV use mainly CXCR4 as the coreceptor. HIV coreceptor usage largely depends on hypervariable regions of the V3 loop located on the viral envelope protein gp120. Binding of gp120 with CD4 and the appropriate coreceptor results in a conformational change and unmasking of a second viral envelope protein called gp41. gp41 subsequently interacts with the host cell membrane, resulting in fusion of the viral envelope with the cell. Subsequent transfer of viral genetic information into the host cell allows for the continuation of viral replication.
M-tropic viruses appear to be preferentially transmitted by sexual contact and constitute the vast majority of virus present in newly infected individuals. 4 Infection of host cells with M-tropic HIV is usually associated with the virus gaining entry into the cell via the formation of the ternary complex of CCR5/CD4/gp120. It has been proposed that a pharmacological agent that would inhibit the interaction of gp120 with CCR5/CD4 would be a useful therapeutic in the treatment of this disease. Indeed, this is an area of intense study in a number of the major HIV research laboratories around the world.
Evidence that such an approach could result in an effective therapy comes from a subpopulation of patients who have been shown to have a mutation in their CCR5 receptor, termed ∆35 CCR5. 5, 6 Homozygous patients have been shown to be resistant to HIV infection, demonstrating that this route of viral entry into the cell is indeed clinically important. Moreover, in vitro studies have demonstrated that addition of ligands selective for CCR5 as well as CCR5-neutralizing antibodies to cells can block HIV viral/host cell fusion. [7] [8] [9] The use of live HIV virus in screening for pharmacological inhibitors raises several issues for the pharmaceutical discovery laboratory. For large-scale screening, it is not feasible to use live virus due to the potential biological hazards and the requirement for all studies to be carried out in a P3-class facility. Previously, this issue has been overcome by relying on a surrogate assay to replace the virus, such as measuring inhibition of ligand binding to CCR5 (e.g., inhibition of MIP-1α binding). Although successful in attaining active compounds that block HIV entry into the host cell, this approach faces the possibility of missing key inhibitors of ternary complex formation, which do not bind directly to or exclusively with the CCR5 chemokine-binding site. Indeed, it has been shown that gp120 interacts with a number of sites on the CCR5 receptor, at least one of which is distinct from that involved with chemokine binding. 10 In addition, allosteric inhibitors that prevent the envelope of HIV from interacting with CCR5 but that do not interfere with MIP-1α binding would also be overlooked in such an assay. Thus, an assay that more closely approximates all the events involved in viral binding and fusion would significantly increase the chance of discovering selective chemical entities that inhibit HIV entry into cells while minimizing the unwanted mechanism of antagonizing chemokine function. Such an assay would have the added benefit of precisely narrowing in on the antiviral mechanism, a disadvantage inherent in more traditional HIV replication assays.
In the present study, we have developed an assay that models the interaction and fusion of HIV with the host cell and is also amenable to a high-throughput screening (HTS) environment. Although it would be desirable to replace the use of virus in the assay with a stable cell line that expresses certain HIV gene products, this is not feasible due to cytotoxic effects when these proteins are overexpressed in cells over the entire cell cycle. In addition, traditional methods for transient gene delivery, such as liposomes or electroporation, present difficulties in adapting assays to automation. Thus, we describe the use of BacMam virus technology to deliver the necessary HIV gene products to a donor mammalian cell to mimic HIV-infected cells in this assay. BacMam viruses are recombinant baculoviruses modified to contain mammalian cell active transcription cassettes in their genomes. These viruses have been demonstrated to efficiently deliver their DNA and direct heterologous gene expression in a wide variety of mammalian cell types. 11 Gene delivery is achieved by a simple liquid addition of BacMam virus to target cells without the need for special formulations or washing steps. Furthermore, levels of gene expression can be controlled by modulation of virus multiplicity or by media additives, thus providing a versatile system to obtain transient gene expression. 12 In the present assay, human embryonic kidney (HEK-293) cells are transduced with individual BacMam baculoviruses expressing gp160 (the membrane-bound precursor of the viral envelope proteins gp120 and gp41), the viral protein rev, and the cytoplasmic viral transcription factor tat. These cells are subsequently mixed with a reporter human osteosarcoma (HOS) cell line that stably expresses hCCR5/hCD4 and a long terminal repeat (LTR)-luciferase reporter construct. Fusion of the cells by the interaction of gp120 to hCCR5/hCD4 results in the transfer of tat protein from the HEK-293 to the HOS cell cytoplasm. tat binds to the LTR on the pro-moter for luciferase in the HOS cell and activates transcription of the luciferase gene, resulting in the production of luciferase, the activity of which can be measured as an endpoint. Thus, we describe how the use of BacMam baculovirus technology results in a dramatic simplification of the assay protocol, resulting in an assay that is ideally suited for HTS.
METHODS

Plasmid generation
The complete coding sequences of HIV-1, tat (GenBank Accession No. X07861) and rev (GenBank Accession No. M34378) were cloned into pcDNA3.1 expression vectors (Invitrogen, Carlsbad, CA) containing G418 and hygromycin resistance genes, respectively. The complete coding sequence of the HIV-1 (YU-2) gp160 envelope gene (nucleotide bases 6181-8893 of GenBank Accession No. M93258) was cloned into a pCR3.1-Uni expression vector (Invitrogen, Carlsbad, CA) containing the G418 resistance gene. The 3 HIV genes were also inserted into the baculovirus shuttle vector, pFastBacMam1, 13 under the transcriptional control of the cytomegalovirus (CMV) promoter. A construction of the pHIV-I LTR containing mutated NFκB sequences linked to the luciferase reporter gene 14 (Promega Corporation Madison, WI) was prepared by digesting pcDNA3.1, containing the G418 resistance gene (Invitrogen, Carlsbad, CA), with Nru I and Bam HI to remove the CMV promoter. LTR-luc was then cloned into the Nru I/Bam HI sites of the plasmid vector. Plasmid preparations (Qiagen, Valencia, CA) were performed after the plasmids were amplified in Escherichia coli strain DH5-alpha (Life Technologies, Rockville, MD). The fidelity of the inserted sequences was confirmed by doublestrand nucleotide sequencing using an ABI Prism Model 377 automated sequencer (Foster City, CA).
BacMam baculovirus generation
Recombinant BacMam baculoviruses were constructed from pFastBacMam shuttle plasmids by using the bacterial cell-based Bac-to-Bac system 15 (Invitrogen, Carlsbad, CA). Viruses were propagated in Sf9 (Spodoptera frugiperda) cells cultured in Hink's TNM-FH insect media (JRH Biosciences, Lenexa, KS) supplemented with 10% (v/v) fetal bovine serum (Hyclone, Ogden, UT) and 0.1% (v/v) pluronic F-68 (Invitrogen, Carlsbad, CA) according to established protocols. 16 Cell culture HOS cells expressing hCCR5 and hCD4 17 were transfected with the pHIV-LTR-luciferase plasmid using FuGENE 6 (Roche Diagnostics Corp., Indianapolis, IN). Single cells were isolated and grown under selection conditions to generate a stable HOS (hCCR5/hCD4/pHIV-LTR-luciferase) clonal cell line. The cells were maintained in Dulbeccos Modified Eagles media (DMEM) supplemented with 10% fetal calf serum (FCS), 1× nonessential amino acids (NEAA), G418 (400 µg/mL), puromycin (1 µg/mL), mycophenolic acid (40 µg/mL), xanthine (250 µg/mL), and hypoxanthine (13.5 µg/mL) to maintain a selection pressure for cells expressing the LTR-luciferase, hCCR5, and hCD4, respectively. HEK-293 cells, stably transfected to express the human macrophage scavenging receptor (Class A, Type 1; GenBank Accession No. D90187), were maintained in DMEM/F-12 media (1:1 mix) supplemented with 10% FCS and 1 µg/mL puromycin. The expression of this receptor by the HEK-293 cells enhances their ability to stick to tissue culture-treated plasticware. All media, serum, and supplements were supplied by Invitrogen (Carlsbad, CA).
Transduction of HEK-293 cells
HEK-293 cells (95%-97% confluent) were harvested using an enzyme-free cell dissociation buffer (Invitrogen, Carlsbad, CA). Then, 5 mL of this solution was added and allowed to wash over the cells for 30 sec. The solution was then removed, and the cells returned to the incubator for 5 min. DMEM/F-12 media supplemented with 10% FCS and 1 µg/mL puromycin were then added to the cells, and the flask was sharply tapped to remove the cells. The cells were collected and counted and diluted into fresh serum containing media. Tranductions were performed by direct addition of BacMam baculovirus containing insect cell media to cells. The cells were simultaneously transduced with BacMam baculovirus expressing tat (1.3 × 10 8 pfu/mL), rev (1.5 × 10 8 pfu/mL), and gp160 (1.0 × 10 8 pfu/mL). Routinely, 2% (v/v) of each virus was added to the media containing the cells. Then, 2 mM butyric acid was also added to the cells at this stage. Previous studies using BacMam baculoviruses have shown that addition of butyric acid can increase protein expression in transduced cells and increase the assay signal. 13 The cells were subsequently mixed and plated at a density of 20,000 cells per well in a final volume of 100 µL in 96well CulturPlate plates (Packard, Meridien, CT). The cells were incubated at 37°C, 5% CO 2 , 95% humidity for 24 h to allow for protein expression.
Transfection of HEK-293 cells
HEK-293 cells were harvested as described above and plated at a density of 20,000 cells per well in a 50-µL volume in 96-well CulturPlate plates (Packard, Meridien, CT). Plasmid DNA encoding tat, gp160, and rev was added to serum-free DMEM/F-12 media containing FuGENE transfection reagent (Roche, Indianapolis, IN), per the manufacturer's instructions (DNA/FuGENE ratio of 1:3). Following a 30-min incubation, serum containing media was added to the transfection mix, and 50 µL of this mix was added to each well to give 0.05 µg of total DNA per well. The cells were incubated at 37°C (5% CO 2 , 95% air) for 24 h to allow for protein expression.
Cell/cell fusion assay format
The media were aspirated from the HEK-293 cells, and 50 µL of DMEM/F-12 media containing 2% FCS and 1× NEAA, plus or minus compounds in 2% DMSO, was added to the cells. HOS cells were harvested as described above and were added to the 96-well plate at a density of 20,000 cells per well in a volume of 50 µL of DMEM/F-12 media containing 2% FCS and 1× NEAA. Following these additions, the cells were returned to a tissue culture incubator (37°C; 5% CO 2 /95% air) for an additional 24 h. The final DMSO concentration in the assay was maintained at 1% unless stated otherwise.
Monoclonal antibodies raised against human CD4, CXCR4, and CCR5 were obtained from BD Biosciences-Pharmingen (San Diego, CA). Polyclonal antibody raised against gp120 was obtained from US Biological (Swampscott, MA), and mouse IgG control antibody was from Sigma (St. Louis, MO).
Measurement of luciferase production
Following the 24-h incubation, total cellular luciferase activity was measured using the LucLite Plus assay kit (Packard, Meridien, CT). In brief, 100 µL of this reagent was added to each well. The plates were sealed and mixed. The plates were dark adapted for approximately 10 min prior to the luminescence being read on a Packard TopCount (data mode: luminescence; count time: 10 sec).
Viral/HOS fusion assay
HOS cells were resuspended in DMEM supplemented with 2% FCS and 1× NEAA. The cells were dispensed into 96-well tissue culture-treated plates (6000 per well; 50 µL) and placed in a humidified incubator (37°C, 5% CO 2 /95% air) overnight. The following day, 50 µL of compounds in the above media was added to each well, and the incubation was continued for a further 1 h. An additional 60 µL of compound in media was transferred to a 96well plate, and 60 µL of HIV-1 (R5 tropic virus) was added to each well and thoroughly mixed. An aliquot (100 µL) of the HIV/compound mixture was subsequently transferred to the wells containing cells/compound. The plates were placed in a humidified incubator at 37°C (5% CO 2 /95% air) for 72 h. Following this incubation period, 150 µL of supernatant was removed, and 50 µL of reconstituted LucLite Plus reagent was added to each well. The luciferase activity of each sample was determined as described above.
Statistical analysis of data
ANOVA (single-factor analysis tool) was performed to determine whether 2 populations were equal. A value of p < 0.05 was taken as being statistically significant. Linear regression analysis was performed using Microsoft Excel, and r 2 values were generated to determine if a correlation existed between data sets. Z′ fac-
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tor values were calculated using the equation defined by Zhang et al. 18 :
Z′ factor = 1 -((3 × SD high + 3 × SD low )/(Mean high -Mean low )). SD high and SD low are defined as the corresponding standard deviations of the Mean high and Mean low values, where high and low refer to the maximum and minimum signal produced by the system.
RESULTS
The effect of viral concentration, rev, and butyric acid on cell/cell fusion HEK-293 cells were transduced with increasing concentrations of BacMam baculovirus that encoded the proteins rev, tat, and gp160 to determine optimal transduction conditions. In addition, the effects of rev and butyric acid on signal size were also examined ( Fig. 1A,B ). As shown in Figure 1 , in the absence of butyric acid, the signal was significantly less than that obtained by transfection produced under identical conditions, even at high virus concentrations tested (3.08 ± 0.15 × 10 6 cps for transfection vs. 1.07 ± 0.08 × 10 6 cps in cells pretreated with 8.3% (v/v) of each BacMam baculovirus). In the absence of rev, the signal was significantly smaller compared to cells transduced with rev, tat, and gp160 BacMam (0.57 ± 0.01 × 10 6 cps vs. 1.07 ± 0.08 × 10 6 cps, respectively; p < 0.001). Under these conditions, the assay was not suitable for screening purposes due to the small window achieved (2.6 ± 0.2-fold increase for cells treated with 8.3% (v/v) of each BacMam baculovirus compared with non-virus-treated control) and the large amounts of virus required.
As shown in Figure 1B , addition of butyric acid resulted in a dramatic increase in the luciferase signal observed in the assay. In the absence of rev, the signal observed at the highest virus concentration tested is similar to that observed under transfection conditions (2.31 ± 0.05 × 10 6 cps with BacMam vs. 2.05 ± 0.07 × 10 6 cps with transfection). In the presence of rev and butyric acid, the signal is significantly greater than in the absence of butyric acid (10.90 ± 0.31 × 10 6 cps vs. 0.55 ± 0.03 × 10 6 cps, respectively, in cells pretreated with 2% of each BacMam baculovirus; p < 0.001).
In the presence of butyric acid, there is a linear correlation of signal size with respect to virus concentration (r 2 = 0.9976; Fig. 1C ). This correlation is maintained up to the addition of 3.3% of each virus (rev, tat, and gp160). At higher virus concentrations, the signal decreases and the standard deviation values increase. This may in part be due to cytotoxic issues related to the processing and expression of the viral proteins. The maximum signal achieved in the assay with 3.3% (v/v) of rev, tat, and gp160 in the presence of butyric acid was 5.8 ± 0.1-fold greater than the signal achieved with transfection. However, for screening purposes, 2% (v/v) each of rev, tat, and gp160 (~10 pfu/cell/virus) in the presence of 2 mM butyric acid was chosen. These conditions produced a robust signal that was well within the linear range with respect to virus concentration (Fig. 1C) . In addition, a significant reduction in the require-ment for virus could be achieved. Under these conditions, the signal produced was found to be 5.3 ± 0.4-fold greater when compared with the transfection assay.
Serum and DMSO tolerance study
The effects of serum and DMSO on amplitude of the assay signal were examined to determine assay tolerances for both ( Fig.  2A,B) . The assay was performed in the presence of increasing concentrations of fetal calf serum (0%-10%) and DMSO (0%-2%). In- 
Time course of fusion assay
The data presented in Figure 2C demonstrate that following the addition of the HOS reporter cell line, there is a lag of 6 h before a significant increase in cellular luciferase activity is observed. Luciferase activity continues to increase for approximately 20 h before reaching a plateau. The signal remains unchanged for a period of 6 h before significantly decreasing, providing a sizable time window within which samples may be assayed.
Effect of selective antibodies on cell/cell fusion
The specificity of the gp120/CCR5/CD4 interaction involved in the cell/cell fusion process induced in this assay can be confirmed by using antibodies that should either selectively block the fusion or would be predicted to have no effect. Antibodies raised against hCD4, hCXCR4, hCCR5, gp120, and IgG were examined. As shown in Figure 3 , antibodies against hCD4, hCCR5, and gp120 all produced a decrease in cell/cell fusion (90.81% ± 0.91%, 95.25% ± 0.28%, and 71.86% ± 1.58% decrease, respectively) at 50 µg/mL of antibody compared with the values obtained in the absence of antibody. These decreases are significant when compared to the effects of a nonspecific IgG antibody (p < 0.001 for hCD4, hCCR5, and gp120 at 50 µg/mL). In contrast, antibodies to CXCR4 had no significant effect on cell/cell fusion when compared with a nonspecific IgG antibody up to a concentration of 50 µg/mL (p = 0.27).
Effect of CCR5 receptor antagonists on cell/cell fusion
Pharmacological characterization of the assay was performed using 2 published standard CCR5 antagonists, SCH-351125 19 and TAK-779, 20 that have previously been shown to selectively antagonize MIP-1α/CCR5 receptor binding. On combining the 2 cell types, the maximum cellular fusion was defined as the level of luciferase activity in the absence of test drug; zero fusion was defined as the level of luciferase activity observed in the presence of 10 µM of the positive control CCR5 binding-antagonist SCH-351125. As shown in Figure 4A , SCH-351125 and TAK-779 both produced a significant concentration-dependent decrease in cell/cell fusion in this present assay (pIC 50 values of 7.63 ± 0.11 and 7.66 ± 0.05, respectively). 
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Correlation of compound IC 50 data from cell/ cell fusion assay with viral/HOS fusion assay
A series of 8 compounds that included SCH-351125 and TAK-779, which had previously been shown to selectively inhibit binding of MIP-1α to the CCR5 receptor, was examined in the BacMam fusion assay. pIC 50 data were determined for each compound and were found to be comparable with data obtained from the viral/HOS fusion assay. 17 As highlighted in Figure 4B , a significant correlation between pIC 50 data was observed for the CCR5 antagonists tested (r 2 = 0.8705).
Comparison of BacMam fusion assay with transfection fusion assay
A comparison of the main parameters of the BacMam fusion assay versus the transfection fusion assay is shown in Table 1 . The data demonstrate that the Z′ factor for the BacMam assay were similar to that observed for the transfection assay (Z′ factors of 0.68 and 0.69, respectively). In addition, the fold increase in signal was similar between the 2 assays (11.50 ± 0.62-fold vs. 15.37 ± 0.55-fold, respectively), although the absolute signal size for each assay was different. The optimal conditions for the present BacMam-derived fusion assay for HTS purposes are highlighted in Figure 5 .
DISCUSSION
Most current therapies for the treatment of HIV rely on inhibiting the replication of the virus once it has entered the host cell. However, there is increasing evidence to suggest that inhibition of viral entry into the host cell may be a viable therapy in the treatment of this disease. It is now clear that HIV entry into cells is a highly organized event. HIV enters the host cell by binding of the specific viral envelope protein gp120 to the host cell coreceptor, CCR5/CD4, on the surface of the cell membrane. Inhibition of this interaction may prevent viral infection and replication. [7] [8] [9] To date, the overriding difficulty in developing antiviral drugs targeting this mechanism is the necessity to use live HIV when assaying compounds that inhibit HIV/cell fusion. For the purposes of screening large libraries of compounds, this is unfeasible mainly due to the potential hazard posed by the virus itself and the requirement for all studies to be performed in a P3-class facility. One alternative approach that has been used is radioligand binding using a known CCR5 ligand. Although such an approach has provided a number of selective CCR5 ligands that have efficacy in preventing HIV infection, this approach fails to uncover compounds that interact at distinct allosteric sites. Thus, the development of a highthroughput fusion assay that contains all the components present during viral cell fusion would provide the greatest chance of discovering a diverse set of selective novel molecules with therapeutic potential. The aim of the present study was therefore to develop a surrogate high-throughput virus-free assay system that could be used to functionally determine the efficacy of CCR5 antagonists at inhibiting M-tropic HIV/host cell fusion.
The assay described replaces the live virus with a cell line that transiently expresses both the viral envelope protein gp120 and a viral transcription factor tat. Fusion of this cell with the CCR5/ CD4-expressing reporter cell line, with the subsequent cytosolic transfer of tat, results in activation of the LTR-luciferase gene in the reporter cell line and luciferase production. Initial optimization of the assay revealed that the addition of the HIV protein rev played a significant role in the assay by significantly enhancing the luciferase signal. This was demonstrated to be due to rev-mediated enhancement of expression of the other viral proteins, gp120 and tat (data not shown). It has previously been shown that gp160 expression can be significantly enhanced by rev. 21 The mechanism by which rev enhances tat expression, however, is unclear. In addition, it was found that butyric acid addition was essential for a viable screening assay. It has been shown previously that butyric acid can enhance expression of a number of BacMam-delivered proteins, including 7 transmembrane receptors and ion channels. The specific pharmacological target for butyric acid in this respect is unclear, although it has been shown to inhibit histone deacetylase. 22 An important feature in the development of such a surrogate assay is that it should mimic the interactions that take place when HIV envelope proteins interact with the host cell CCR5/CD4 coreceptor. The cell/cell fusion described in this novel assay has been shown, by use of selective antibodies, to be mediated by CCR5, CD4, and gp120. In addition, the coreceptor for T-tropic strains of HIV, CXCR4, is not involved in the cell/cell fusion examined in this assay. These data demonstrate the suitability of this assay as a specific screen for inhibitors of the M-tropic virus strain. An additional advantage, afforded by the use of BacMam technology, is the potential for screening a number of M-tropic HIV strains in an identical assay format by simply changing the BacMam gp160 virus between assays. This minimizes the requirement for multiple assay formats.
Pharmacological characterization reveals a close correlation between CCR5 antagonist IC 50 data obtained in the present cell/ cell fusion assay and that obtained from an HIV-1 replication assay. It has previously been shown that the HOS cell line can efficiently support HIV infection. 17 These data validate the utility of the cell/cell fusion assay as a valuable tool for identifying small molecules that block the early stages of HIV-1 replicationnamely, virus-receptor attachment, fusion, and entry.
Several novel cell/cell fusion assays that mimic HIV/cell fusion have been reported in the literature. 23, 24 However, these assays rely on laborious and costly transfection steps, making them less than suitable for HTS. In the present study, a comparison of BacMam baculovirus gene transfer technology with traditional transfection methods demonstrates that BacMam is a simple, non-laborintensive, and inexpensive alternative to traditional lipid-based transfection methods. In addition, the signal obtained is robust and reproducible.
In conclusion, the novel cell/cell fusion assay described has been shown to be useful as a surrogate assay for traditional and lower throughput HIV replication assays and has the potential to play a valuable role in the discovery of a novel therapy for the treatment of HIV.
